Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity

Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A

(2014) A. Muto et al.   BLOOD

The Potency of Erythropoietin-Mimic Antibodies Correlates Inversely with Affinity

(2014) S. E. Lacy et al.   JOURNAL OF IMMUNOLOGY

Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

(2013) A. Muto et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

(2013) Zenjiro Sampei et al.   PLoS One

Engineering an Improved IgG4 Molecule with Reduced Disulfide Bond Heterogeneity and Increased Fab Domain Thermal Stability

(2012) Shirley J. Peters et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Disulfide bond structures of IgG molecules

(2012) Hongcheng Liu et al.   mAbs

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

(2012) Takehisa Kitazawa et al.   NATURE MEDICINE

Mechanism of Immunoglobulin G4 Fab-arm Exchange

(2011) Theo Rispens et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Engineering the variable region of therapeutic IgG antibodies

(2011) Tomoyuki Igawa et al.   mAbs

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Optimization of Fc-mediated effector functions of monoclonal antibodies

(2009) William R Strohl   CURRENT OPINION IN BIOTECHNOLOGY

Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass

(2008) Thomas M. Dillon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY